- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01334060
WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (WIN)
The study is not currently recruiting new subjects due to an interruption in funding from its sponsors. Efforts are under way to re-establish funding, however, the study is currently on-hold pending the outcome of these re-funding efforts. There have been no safety concerns identified during the study
This is an open label, single dose level, phase II study in two patient groups (CML and AML) using genetic randomisation. Consented and eligible HLA A2+ve patients will be vaccinated with two DNA vaccines and HLA A2 -ve patients will be followed up with molecular monitoring only. The objectives are to evaluate: 1) Molecular response following p.DOM-epitope DNA vaccination in patients with CML (BCR-ABL, WT1) and AML (WT1) at weeks 4, 8, 12, 16, 20 and at months 6, 12, 18 and 24. 2) Time to disease progression, 2 year survival rate (patients with AML) 3) Correlation of molecular responses with immunological responses. Primary Objective: CML: Molecular response of BCR-ABL. AML: Time to disease progression. Secondary Objective: Molecular response of WT1 transcript levels, immune responses to WT1 and DOM, Toxicity, CML-Time to disease progression, next treatment and survival, AML-2 year survival, overall survival
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Exeter, United Kingdom, EX2 5DW
- Royal Devon and Exeter NHS Foundation Trust
-
London, United Kingdom, W12 0HS
- Imperial College NHS Trust
-
Southampton, United Kingdom, SO16 6YD
- Southampton University Hospitals NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CML patients:
Philadelphia chromosome positive CML in chronic phase, in complete cytogenetic response (CCyR) but with detectable BCR-ABL transcripts and maintained the CCyR on imatinib monotherapy for a minimum of 24 months
AML patients:
WT1+ AML in CR or morphologic CR with incomplete blood count recovery (CRi);
All patients:
- ≥ 18 years of age, written informed consent
- Performance status of 0 or 1.
- for vaccination groups: HLA-A0201 positive in at least one allele
- for control groups: HLA A2 negative in both alleles
- renal function and liver function (Creatinine <1.5 x upper limit of normal, liver function tests < 1.5 x upper limit of normal); Lymphocyte count > 1.0 x109/l; normal clotting
- HB>100 g/l
- Adequate venous access for repeated blood sampling according to protocol schedule.
- If sexually active and possibly fertile, patients must agree to use appropriate contraceptive methods during the trial and for six months afterwards.
Exclusion Criteria:
CML patients:
- CML in accelerated phase or blast crisis or having achieved CMR at any point during imatinib therapy.
- Imatinib dose modification in the previous year, Imatinib interruption for more than 15 days in the previous 6 months to enrolment
- Prior interferon-α therapy
- hypocellular bone marrow (<20%)
- Complete molecular response (CMR)
AML patients:
- AML in haematological relapse or eligible for allogeneic SCT.
- hypocellular bone marrow (<20%)
- AML patients with the "good-risk" abnormalities comprised by the core binding factor leukaemias (i.e., AML with the translocation (8;21) and inversion of chromosome 16, and acute promyelocytic leukaemia with the translocation (15;17))
All patients:
- Systemic steroids or other drugs with a likely effect on immune competence are forbidden during the trial. The predictable need of their use will preclude the patient from trial entry
- Major surgery in the preceding three to four weeks from which the patient has not yet recovered.
- Patients who are of high medical risk because of non-malignant systemic disease, as well as those with active uncontrolled infection.
- Patients with any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial, such as concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/ IV cardiac disease
- Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.
- Patients who are serologically positive for or are known to suffer from Hepatitis B, C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: CML HLA A2-
|
|
NO_INTERVENTION: AML HLA A2-
|
|
EXPERIMENTAL: AML HLA A2+
|
p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals.
Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months.
The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
|
EXPERIMENTAL: CML HLA A2+
|
p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals.
Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months.
The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Molecular response following p.DOM-epitope DNA vaccination in patients with CML (BCR-ABL, WT1) and AML (WT1)
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CML-Time to disease progression, next treatment and survival
Time Frame: 2 years
|
2 years
|
AML-2 year survival, overall survival
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood. 2008 Oct 1;112(7):2956-64. doi: 10.1182/blood-2008-02-137695. Epub 2008 May 23.
- Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008 Feb;8(2):108-20. doi: 10.1038/nrc2326.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RHMCAN0700
- 2009-017340-14 (EUDRACT_NUMBER)
- ISRCTN62678383 (REGISTRY: NCRN)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukaemia (Acute)
-
University Hospital TuebingenUniversity Hospital of CologneCompletedAcute LeukaemiaGermany
-
University of LeipzigCompletedAcute Myeloid LeukaemiaGermany
-
University of SydneyMelbourne Health; Royal Brisbane and Women's HospitalUnknown
-
Great Ormond Street Hospital for Children NHS Foundation...Wellcome TrustRecruitingRelapsed Acute Myeloid LeukaemiaUnited Kingdom
-
University Hospital Southampton NHS Foundation...Royal Free and University College Medical SchoolCompletedLymphoma | Myeloma | Acute Leukaemia | Chronic LeukaemiaUnited Kingdom
-
University Hospital, Strasbourg, FranceUnknown
-
AstraZenecaCompletedAcute | Leukaemia | Myelocytic
-
Peking University People's HospitalMinistry of Science and Technology of the People´s Republic of ChinaNot yet recruitingAcute Promyelocytic Leukaemia
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedAcute Myeloid LeukaemiaFrance, United States, Australia
-
GlaxoSmithKlineCompletedLeukaemia, Myelocytic, AcuteUnited States
Clinical Trials on p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine
-
University Hospital, AntwerpKom Op Tegen Kanker; Stichting tegen KankerRecruitingEsophageal Cancer | Ovarian Cancer | Pancreas Cancer | Liver CancerBelgium
-
Sellas Life Sciences GroupCompletedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndrome (MDS)United States
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)United States
-
National Institute of Allergy and Infectious Diseases...The Emmes Company, LLCCompleted
-
Eli Lilly and CompanyMemorial Sloan Kettering Cancer CenterCompleted
-
Washington University School of MedicineSusan G. Komen Breast Cancer FoundationCompletedTriple Negative Breast Cancer | Triple Negative Breast Neoplasms | Triple-Negative Breast CancerUnited States
-
French National Agency for Research on AIDS and...CompletedChronic Hepatitis BFrance
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States